Avivagen Inc. (VIV:TSX.V) announced in a news release the first order from Taiwan came in for its OxC-beta Livestock.
More Standing Enterprise Co., a manufacturer of animal nutrition products, bought 200 kilograms of Avivagen's proprietary product for use in poultry and sow feeds. OxC-beta Livestock is shown to be an effective, economic replacement for antibiotics in livestock feeds.
"Today's new order is further evidence that feed producers around the world are recognizing the substantial benefit that OxC-beta Livestock provides in improving the health and performance of multiple food-producing animal species and allowing the phasing out of nonmedicinal use of antibiotics," Avivagen CEO Kym Anthony said in the release.
Taiwan represents a new, robust growth market for Avivagen's OxC-beta Livestock in that it produces about 3.25 million tons of sow feed and nearly 3.5 million tons of poultry feed each year.
"Beyond Taiwan, use of OxC-beta Livestock has been ramping up steadily in the Philippines and Thailand, and Avivagen believes that the scale-up of OxC-beta Livestock use in Taiwan will mirror that of other markets in the region," the release noted.
Read what other experts are saying about:
Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Avivagen. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.
